Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Mar 20;42(9):994-1000.
doi: 10.1200/JCO.23.00137. Epub 2024 Jan 22.

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Dennis J Slamon  1 , Véronique Diéras  2 , Hope S Rugo  3 , Nadia Harbeck  4 , Seock-Ah Im  5 , Karen A Gelmon  6 , Oleg N Lipatov  7 , Janice M Walshe  8 , Miguel Martin  9 , Mariana Chavez-MacGregor  10 , Eustratios Bananis  11 , Eric Gauthier  12 , Dongrui R Lu  13 , Sindy Kim  13 , Richard S Finn  1
Affiliations
Randomized Controlled Trial

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Dennis J Slamon et al. J Clin Oncol. .

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.PALOMA-2 demonstrated statistically and clinically significant improvement in progression-free survival with palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC). Here, we report results for the secondary end point overall survival (OS). Postmenopausal women (N = 666) with ER+/HER2- ABC without previous systemic therapy for ABC were randomly assigned 2:1 to palbociclib plus letrozole or placebo plus letrozole. After a median follow-up of 90.1 months, 405 deaths were observed and 155 patients were known to be alive. The median OS was 53.9 months (95% CI, 49.8 to 60.8) with palbociclib plus letrozole versus 51.2 months (95% CI, 43.7 to 58.9) with placebo plus letrozole (hazard ratio [HR], 0.96 [95% CI, 0.78 to 1.18]; stratified one-sided P = .34). An imbalance in the number of patients with unknown survival outcome between the treatment arms (13.3% v 21.2%, respectively) limited interpretation of OS results. With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided P = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.

Trial registration: ClinicalTrials.gov NCT01740427.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Figures

FIG 1.
FIG 1.
OS in the ITT population and by subgroup. (A) Kaplan-Meier curve of OS in the ITT population. (B) Forest plot of OS by subgroup. (C) Kaplan-Meier curve of OS in the ITT population after recovery of data. (D) Forest plot of OS by subgroup after recovery of data. ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; LET, letrozole; NE, not estimable; OS, overall survival; PAL, palbociclib; PBO, placebo.
FIG 2.
FIG 2.
OS and time to chemotherapy. (A) Kaplan-Meier curve of OS in the ITT populations of both PALOMA-1 and PALOMA-2. Control arm was LET alone in PALOMA-1and PBO plus LET in PALOMA-2. Kaplan-Meier curve (B) for time to first subsequent chemotherapy and (C) after censoring for deaths without chemotherapy. HR, hazard ratio; ITT, intent-to-treat; LET, letrozole; OS, overall survival; PAL, palbociclib; PBO, placebo; TTC, time to chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Finn RS, Dering J, Conklin D, et al. : PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77, 2009 - PMC - PubMed
    1. Beaver JA, Amiri-Kordestani L, Charlab R, et al. : FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21:4760-4766, 2015 - PubMed
    1. Wedam S, Fashoyin-Aje L, Bloomquist E, et al. : FDA approval summary: Palbociclib for male patients with metastatic breast cancer. Clin Cancer Res 26:1208-1212, 2020 - PubMed
    1. IBRANCE Capsules, palbociclib. New York, NY, Pfizer, 2019
    1. McAndrew NP, Finn RS: Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract 18:319-327, 2022 - PubMed

Publication types

Associated data